NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.…
NEXGEL to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 19th
NEXGEL (NASDAQ: NXGL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 3.121 USD on 20 November 2026, down 93.5% over 52 weeks. Its 52-week range is 3.000 USD to 51.20 USD: the price is 93.9% below the high and 4.0% above the low.
Its market capitalisation is 1.67M USD.
NEXGEL reports return on equity of -67.3%, an operating margin of -58.6% and revenue up 8.3% year over year.
Its debt exceeds its cash by 9.25M USD, a debt-to-equity ratio of 0.69. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 23 March 2027.